EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial
- 12 August 2013
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 73 (2), 472-474
- https://doi.org/10.1136/annrheumdis-2013-203736
Abstract
Recently, the European League Against Rheumatism (EULAR) developed the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).3 ESSDAI was shown to be able to monitor disease activity in patient profile and open-label studies.4 , 5 To further study the utility of ESSDAI for clinical studies, we assessed the responsiveness of ESSDAI after rituximab treatment in a randomised controlled trial (RCT) of patients with pSS.6Keywords
This publication has 7 references indexed in Scilit:
- Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximabAnnals Of The Rheumatic Diseases, 2012
- Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?Expert Opinion on Biological Therapy, 2011
- Treatment of Primary Sjögren SyndromeJAMA, 2010
- Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity IndexArthritis Care & Research, 2010
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Methods for assessing responsivenessJournal of Clinical Epidemiology, 2000